Vanlev omapatrilat: Phase II data; Phase III

In a 573-patient Phase II trial, omapatrilat and the marketed ACE inhibitor lisinopril produced similar improvement in treadmill tests and overall cardiovascular function after 12 weeks of treatment. However, death or hospitalization for heart failure was seen in 29 percent of the lisinopril group compared to 16 percent of the omapatrilat group. ...